Zimmer Biomet (ZBH) Earns Daily Media Sentiment Score of 0.20
News stories about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 47.2883150987969 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- KFx inks Zimmer licensing deal, sues Stryker over patent infringement (massdevice.com)
- KFx Medical, LLC Inks 5th Knotless Double Row Patents License (oleantimesherald.com)
- Zimmer Biomet (ZBH) Earns Neutral Rating from Analysts at BTIG Research (americanbankingnews.com)
- Judge tosses Zimmer Biomet hip suit over statute of limitations issues (massdevice.com)
- Global Knee Replacement Market 2024 : Zimmer Biomet Holding Inc., Stryker Corporation, Smith & Nephew, Johnson … (mymarketgazette.com)
A number of equities analysts have weighed in on ZBH shares. Morgan Stanley reduced their price objective on shares of Zimmer Biomet from $148.00 to $140.00 and set an “overweight” rating for the company in a research report on Friday, April 27th. Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Tuesday, July 17th. Argus cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Friday, June 22nd. Needham & Company LLC upped their price objective on shares of Zimmer Biomet from $146.00 to $150.00 and gave the stock a “strong-buy” rating in a research report on Monday, July 30th. Finally, ValuEngine cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Thursday, June 7th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $135.43.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Friday, July 27th. The medical equipment provider reported $1.92 EPS for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.99 billion. Zimmer Biomet had a net margin of 21.67% and a return on equity of 13.53%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.08 earnings per share. equities research analysts predict that Zimmer Biomet will post 7.67 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend was Thursday, June 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 11.96%.
In related news, VP Tony W. Collins sold 2,778 shares of the company’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $125.77, for a total value of $349,389.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Katarzyna Mazur-Hofsaess sold 8,765 shares of the company’s stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $113.61, for a total transaction of $995,791.65. Following the completion of the sale, the insider now directly owns 25,447 shares of the company’s stock, valued at approximately $2,891,033.67. The disclosure for this sale can be found here. 0.71% of the stock is owned by corporate insiders.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: Book Value Per Share – BVPS
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.